belantamab mafodotin + nirogacestat + pomalidomide

This combination therapy consists of the antibody-drug conjugate (ADC) belantamab mafodotin, the gamma-secretase inhibitor nirogacestat, and the immunomodulatory agent pomalidomide. It is currently being investigated in a Phase 1 dose-escalation study led by Memorial Sloan Kettering Cancer Center for the treatment of relapsed or refractory multiple myeloma. Belantamab mafodotin targets B-cell maturation antigen (BCMA) on the surface of myeloma cells to deliver the cytotoxic microtubule inhibitor monomethyl auristatin F (MMAF). Nirogacestat is included in the regimen to inhibit gamma-secretase, an enzyme responsible for the cleavage and shedding of BCMA from the cell surface; by preventing this shedding, nirogacestat potentially increases BCMA density and enhances the binding and efficacy of the ADC. Pomalidomide further augments the anti-tumor response through its immunomodulatory effects. While belantamab mafodotin previously received accelerated FDA approval as a monotherapy, that approval was withdrawn in 2023 following the results of the DREAMM-3 trial.

Brand names

BlenrepOgsiveoPomalyst

Other names

belantamab mafodotin-blmf